Bitcoin halving
What does that mean?
$2.77T
Total marketcap
$109.73B
Total volume
BTC 49.72%     ETH 15.35%
Dominance

Lantheus LNTH Stock

62.24 USD {{ price }} 2.944099% {{change_pct}}%
Exchange
NasdaqGM
Market Cap
4.27B USD
LOW - HIGH [24H]
60.31 - 62.47 USD
VOLUME [24H]
987.42K USD
{{ volume }}
P/E Ratio
13.38
Earnings per share
4.65 USD

Lantheus Price Chart

Lantheus LNTH Financial and Trading Overview

Lantheus stock price 62.24 USD
Previous Close 86.2 USD
Open 86.36 USD
Bid 0 USD x 1200
Ask 0 USD x 1200
Day's Range 85.65 - 90.34 USD
52 Week Range 47.46 - 100.85 USD
Volume 1.05M USD
Avg. Volume 1.03M USD
Market Cap 6.16B USD
Beta (5Y Monthly) 0.677464
PE Ratio (TTM) N/A
EPS (TTM) 4.65 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 122.38 USD

LNTH Valuation Measures

Enterprise Value 6.01B USD
Trailing P/E N/A
Forward P/E 14.627036
PEG Ratio (5 yr expected) 0.41
Price/Sales (ttm) 5.9939156
Price/Book (mrq) 13.766093
Enterprise Value/Revenue 5.848
Enterprise Value/EBITDA 40.229

Trading Information

Lantheus Stock Price History

Beta (5Y Monthly) 0.677464
52-Week Change 47.90%
S&P500 52-Week Change 20.43%
52 Week High 100.85 USD
52 Week Low 47.46 USD
50-Day Moving Average 90.37 USD
200-Day Moving Average 71.71 USD

LNTH Share Statistics

Avg. Volume (3 month) 1.03M USD
Avg. Daily Volume (10-Days) 1.16M USD
Shares Outstanding 68.33M
Float 66.85M
Short Ratio 3.34
% Held by Insiders 2.80%
% Held by Institutions 101.29%
Shares Short 3.68M
Short % of Float 7.08%
Short % of Shares Outstanding 5.37%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -1.72%
Operating Margin (ttm) 9.59%
Gross Margin 62.91%
EBITDA Margin 14.53%

Management Effectiveness

Return on Assets (ttm) 5.39%
Return on Equity (ttm) -3.68%

Income Statement

Revenue (ttm) 1.03B USD
Revenue Per Share (ttm) 15.01 USD
Quarterly Revenue Growth (yoy) 44.00%
Gross Profit (ttm) 581.7M USD
EBITDA 149.28M USD
Net Income Avi to Common (ttm) -17702000 USD
Diluted EPS (ttm) -0.26
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 470.86M USD
Total Cash Per Share (mrq) 6.89 USD
Total Debt (mrq) 586.05M USD
Total Debt/Equity (mrq) 131.54 USD
Current Ratio (mrq) 2.798
Book Value Per Share (mrq) 6.524

Cash Flow Statement

Operating Cash Flow (ttm) 380.02M USD
Levered Free Cash Flow (ttm) -151120128 USD

Profile of Lantheus

Country United States
State MA
City Bedford
Address 201 Burlington Road
ZIP 01730
Phone 978 671 8001
Website https://www.lantheus.com
Industry Drug Manufacturers-Specialty & Generic
Sector(s) Healthcare
Full Time Employees 698

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.

Q&A For Lantheus Stock

What is a current LNTH stock price?

Lantheus LNTH stock price today per share is 62.24 USD.

How to purchase Lantheus stock?

You can buy LNTH shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Lantheus?

The stock symbol or ticker of Lantheus is LNTH.

Which industry does the Lantheus company belong to?

The Lantheus industry is Drug Manufacturers-Specialty & Generic.

How many shares does Lantheus have in circulation?

The max supply of Lantheus shares is 68.55M.

What is Lantheus Price to Earnings Ratio (PE Ratio)?

Lantheus PE Ratio is 13.38494600 now.

What was Lantheus earnings per share over the trailing 12 months (TTM)?

Lantheus EPS is 4.65 USD over the trailing 12 months.

Which sector does the Lantheus company belong to?

The Lantheus sector is Healthcare.

Lantheus LNTH included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16379.46 USD
-0.12
4.79B USD 16347.38 USD 16420.92 USD 4.79B USD
NASDAQ Global Market Composite NQGM 2283.98 USD
+0.52
2277.12 USD 2296.84 USD
NASDAQ DM Ex Japan Large Mid Ca NQDMXJPLMAUD 2100.38 AUD 1390.15 USD
<0.01
2100.38 AUD 1390.15 USD 2100.38 AUD 1390.15 USD
NASDAQ HealthCare IXHC 1011.84 USD
-0.04
1011.35 USD 1017.55 USD
NASDAQ Composite Total Return I XCMP 19904.22 USD
-0.12
19865.24 USD 19954.6 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2657.07 USD
+0.1
2653.57 USD 2668.1 USD